NVAC Vaccine Financing Stakeholder Forum - PowerPoint PPT Presentation


PPT – NVAC Vaccine Financing Stakeholder Forum PowerPoint presentation | free to view - id: 20d39-NzFkO


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

NVAC Vaccine Financing Stakeholder Forum


NVAC Vaccine Financing Stakeholders' Forum June 28-29, 2004. NVAC. Vaccine Financing Stakeholder Forum. A Distributor's Perspective. Presented by Brian Cox ... – PowerPoint PPT presentation

Number of Views:51
Avg rating:3.0/5.0
Slides: 10
Provided by: stanbergma


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: NVAC Vaccine Financing Stakeholder Forum

NVAC Vaccine Financing Stakeholder Forum
  • A Distributors Perspective
  • Presented by Brian Cox

Henry Schein, Inc. Overview
  • Henry Schein is one of the largest distributors
    of vaccines in the USA
  • Distribute over 80 vaccine skus through sales
    force of 2,000 team Schein members
  • Vaccines are complemented by over 90,000
    additional skus

Henry Schein, Inc. Overview
  • VFC distributor in 26 States and municipalities
  • Currently averaging over 400 VFC orders per day
  • Distributed 20 million influenza doses in 2003
  • Provide exclusive distribution for a variety of
    vaccine manufacturers

Henry Schein, Inc. Overview
  • Cover all trade classes including office-based
    physicians, GPOs, DoD contracts, vaccine
    clinics, public health, retail pharmacies, etc
  • Henry Schein provides the valuable service of
    uniting health care practitioners with the
    products they need to deliver quality care

Recommendation 1
  • Believe recommendation will improve immunization
    rates across all demographics
  • Have concerns about crossover between insured and
    uninsured. How will this work?
  • What leeway will insurance companies have in
    pricing the vaccine benefit? Impact to patients?

Recommendation 1
  • What will happen with vaccines, like Td, that
    have a new calculated value less than the current
    market price?
  • What will happen with new vaccines that are
    priced above the new calculated price? Will we
    end up with vaccines that are unavailable to
    certain demographics?

Recommendation 1
  • If a voucher program is to be established, what
    would the incremental costs be if this were the
    only option? Are these costs offset by the
    benefits of the insurance mandate? Is it
    beneficial to have both a voucher and insurance

Recommendation 2
  • Expanding the non-voting membership of ACIP is
    important under the new proposed system
  • If not ACIP then another advisory body should be
    set up to work in conjunction with the ACIPs
    scientific contributions

Recommendation 3
  • This should be considered integral to any
    wholesale change in the current vaccine financing
About PowerShow.com